Amgen ( AMGN ) announced that new data from the phase II PEAK study and the phase III PRIME study were presented at the 2015 American Society of Clinical Oncology (ASCO) gastrointestinal cancer symposium. Both the studies are evaluating the first-line use of Vectibix in combination with an oxaliplatin-based chemotherapy regimen, FOLFOX, in patients suffering from wild-type RAS (absence of exons 2, 3, or 4 KRAS or NRAS mutations) metastatic colorectal cancer (mCRC). Results from the PEAK study, which compared Vectibix plus FOLFOX treatment with Roche’s ( RHHBY ) Avastin plus FOLFOX, showed that a significantly higher proportion of patients in the Vectibix treatment group had earlier tumor shrinkage at week eight […]